Hidradenitis Suppurativa

Hidradenitis Suppurativa Trial

Trial ID: NCT05889182

Phase 3 | Oral tablet | 104 week treatment period | 30 day safety follow up

• ≥ 12 years old
• Moderate to Severe Hidradenitis Suppurativa for ≥ 6 months
• Condition has not improved after using anti-TNF treatments such as Humira or other Adalimumab biosimilars for 12 weeks, or could not tolerate treatment
• Condition has not improved after using non-anti-TNF therapy for 16 weeks, or could not tolerate it

Exclusion Criteria:

• Used a JAK inhibitor before, for more than 2 weeks
• Used investigational drugs during the study

Hidradenitis Suppurativa Trial

Phase 2 | Injection | 16 week treatment period | 16 week safety follow up

Trial ID: NCT06118099

• Between 18 and 70 years old
• Moderate to Severe Hidradenitis Suppurativa for ≥ 1 year
• Never used biologic treatments
• Condition has not improved after 12 weeks of oral antibiotics, or could not tolerate treatment

Exclusion Criteria:

• Used a JAK or TYK inhibitor before
• Used anti-OX40 or therapies targeting IL-1, IL-17, or IL-23

Hidradenitis Suppurativa Trial

Phase 3 | Oral tablet | 54 week treatment period

Trial ID: NCT06212999

• ≥ 18 years old
• Moderate to Severe Hidradenitis Suppurativa for ≥ 3 months
• Condition not improved after minimum 3 month systemic treatment (2-12 week washout period required prior to trial participation, if applicable)
• Good general health

Exclusion Criteria:

• Pregnant or breastfeeding women
• Women who are considering pregnancy